192 related articles for article (PubMed ID: 38402904)
1. Tumour-associated neutrophils: Potential therapeutic targets in pancreatic cancer immunotherapy.
Wu Q; Mao H; Jiang Z; Tang D
Immunology; 2024 Jul; 172(3):343-361. PubMed ID: 38402904
[TBL] [Abstract][Full Text] [Related]
2. Neutrophil diversity and plasticity in tumour progression and therapy.
Jaillon S; Ponzetta A; Di Mitri D; Santoni A; Bonecchi R; Mantovani A
Nat Rev Cancer; 2020 Sep; 20(9):485-503. PubMed ID: 32694624
[TBL] [Abstract][Full Text] [Related]
3. Extracellular vesicles in pancreatic cancer immune escape: Emerging roles and mechanisms.
Liu C; He D; Li L; Zhang S; Wang L; Fan Z; Wang Y
Pharmacol Res; 2022 Sep; 183():106364. PubMed ID: 35901939
[TBL] [Abstract][Full Text] [Related]
4. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
[TBL] [Abstract][Full Text] [Related]
5. Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment.
Zhang Y; Guoqiang L; Sun M; Lu X
Cancer Biol Med; 2020 Feb; 17(1):32-43. PubMed ID: 32296575
[TBL] [Abstract][Full Text] [Related]
6. Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy.
Torphy RJ; Schulick RD; Zhu Y
Mol Carcinog; 2020 Jul; 59(7):775-782. PubMed ID: 32166821
[TBL] [Abstract][Full Text] [Related]
7. Emerging trends in the immunotherapy of pancreatic cancer.
Banerjee K; Kumar S; Ross KA; Gautam S; Poelaert B; Nasser MW; Aithal A; Bhatia R; Wannemuehler MJ; Narasimhan B; Solheim JC; Batra SK; Jain M
Cancer Lett; 2018 Mar; 417():35-46. PubMed ID: 29242097
[TBL] [Abstract][Full Text] [Related]
8. Dilemma and Challenge of Immunotherapy for Pancreatic Cancer.
Wu J; Cai J
Dig Dis Sci; 2021 Feb; 66(2):359-368. PubMed ID: 32140943
[TBL] [Abstract][Full Text] [Related]
9. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
[TBL] [Abstract][Full Text] [Related]
10. Harnessing neutrophil plasticity for HCC immunotherapy.
Ramon-Gil E; Geh D; Leslie J
Essays Biochem; 2023 Sep; 67(6):941-955. PubMed ID: 37534829
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Plasticity of Neutrophils: Relevance to Pathogen Responses and Cancer.
Rogers T; DeBerardinis RJ
Trends Cancer; 2021 Aug; 7(8):700-713. PubMed ID: 34023325
[TBL] [Abstract][Full Text] [Related]
12. Do novel treatment strategies enhance T cell-mediated Immunity: Opportunities and challenges in pancreatic cancer immunotherapy.
Luo W; Zheng L; Zhang T
Int Immunopharmacol; 2021 Jan; 90():107199. PubMed ID: 33246828
[TBL] [Abstract][Full Text] [Related]
13. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity.
Xue R; Zhang Q; Cao Q; Kong R; Xiang X; Liu H; Feng M; Wang F; Cheng J; Li Z; Zhan Q; Deng M; Zhu J; Zhang Z; Zhang N
Nature; 2022 Dec; 612(7938):141-147. PubMed ID: 36352227
[TBL] [Abstract][Full Text] [Related]
14. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.
Mundry CS; Eberle KC; Singh PK; Hollingsworth MA; Mehla K
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188387. PubMed ID: 32579889
[TBL] [Abstract][Full Text] [Related]
15. A Novel Molecular Signature of Cancer-Associated Fibroblasts Predicts Prognosis and Immunotherapy Response in Pancreatic Cancer.
Ge W; Yue M; Wang Y; Wang Y; Xue S; Shentu D; Mao T; Zhang X; Xu H; Li S; Ma J; Wang L; Cui J
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613599
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment.
Zhu YH; Zheng JH; Jia QY; Duan ZH; Yao HF; Yang J; Sun YW; Jiang SH; Liu DJ; Huo YM
Cell Oncol (Dordr); 2023 Feb; 46(1):17-48. PubMed ID: 36367669
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil Heterogeneity in Cancer: From Biology to Therapies.
Lecot P; Sarabi M; Pereira Abrantes M; Mussard J; Koenderman L; Caux C; Bendriss-Vermare N; Michallet MC
Front Immunol; 2019; 10():2155. PubMed ID: 31616408
[TBL] [Abstract][Full Text] [Related]
18. Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy.
Elzoghby AO; Ferrone CR; Ferrone S; Nasr ML
Drug Discov Today; 2023 Jan; 28(1):103434. PubMed ID: 36368630
[TBL] [Abstract][Full Text] [Related]
19. A novel target for combination immunotherapy in pancreatic cancer: IL-1β mediates immunosuppression in the tumour microenvironment.
Winograd R; Simeone DM; Bar-Sagi D
Br J Cancer; 2021 May; 124(11):1754-1756. PubMed ID: 33758330
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
Front Immunol; 2018; 9():1878. PubMed ID: 30158932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
